Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk .

Eli Lilly (LLY) stock in focus as the company launches Mounjaro Kwikpen in India, intensifying competition with Novo Nordisk's (NVO) Wegovy. Read more here.

Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market

Eli Lilly launches Mounjaro KwikPen in India, offering adults with type 2 diabetes and obesity a once-weekly, prescription-only treatment.

Eli Lilly and Company (NYSE: LLY) is one of the best upside stocks to invest in now. On August 11, Eli Lilly announced its decision to use the confidential reimbursement price option in Germany for its Type 2 diabetes/T2D treatment,

The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration. It will be available in six strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with prices ranging from ₹14,

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to capture India’s growing anti-obesity market as Novo Nordisk pushes Wegovy.